KJHP
GRCE

K.J. Harrison & Partners’s Grace Therapeutics GRCE Stock Holding History

K.J. Harrison & Partners’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-708
Closed -$28K – 174
2018
Q4 		$28K Buy
+708
New +$30.9K 0.02% 129

Other funds holding GRCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

K.J. Harrison & Partners's GRCE Position: Q1 2019 in Review

K.J. Harrison & Partners sold out of Grace Therapeutics (GRCE) in Q1 2019, closing a stake of 708 shares — an estimated $28K sold.

K.J. Harrison & Partners first reported a position in GRCE in Q4 2018 and held it in 1 quarter. The position peaked at $28K in Q4 2018. 14 funds tracked by Wall St. Rank hold GRCE as of Q1 2019.

  • K.J. Harrison & Partners reported no remaining Grace Therapeutics position as of Q1 2019 after selling out during the quarter.
  • K.J. Harrison & Partners sold 708 Grace Therapeutics shares in Q1 2019, an estimated $28K.
  • K.J. Harrison & Partners first reported a position in Grace Therapeutics in Q4 2018 and held it in 1 quarter.
  • K.J. Harrison & Partners's Grace Therapeutics position peaked at $28K in Q4 2018.
  • 14 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2019.

Based on K.J. Harrison & Partners's 13F filing for Q1 2019, filed 26 Apr 2019.